Plus Therapeutics
Stock Forecast, Prediction & Price Target
Plus Therapeutics Financial Estimates
Plus Therapeutics Revenue Estimates
Plus Therapeutics EBITDA Estimates
Plus Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $224K 0% | $4.91M 2093.30% | Avg: $2.86M Low: $2.42M High: $3.14M avg. -41.65% | Avg: $16.86M Low: $14.27M High: $18.48M avg. 488.31% | Avg: $54.32M Low: $45.98M High: $59.54M avg. 222.13% | Avg: $87.62M Low: $74.17M High: $96.05M avg. 61.29% |
Net Income
% change YoY
| $-14.33M N/A | $-20.83M -45.40% | $-13.31M 36.09% | Avg: $-29.06M Low: $-11.24M High: $-5.05M avg. -118.27% | Avg: $-49.80M Low: $-12.90M High: $-3.73M avg. -71.34% | Avg: $-5.84M Low: $-6.57M High: $-4.67M avg. 88.26% | Avg: $2.15M Low: $1.72M High: $2.42M avg. 136.82% |
EBITDA
% change YoY
| $-12.01M N/A | $-18.94M -57.72% | $-12.69M 33.00% | Avg: $-1.36M Low: $-1.49M High: $-1.15M avg. 89.21% | Avg: $-8.05M Low: $-8.82M High: $-6.81M avg. -488.31% | Avg: $-25.93M Low: $-28.42M High: $-21.95M avg. -222.13% | Avg: $-41.82M Low: $-45.84M High: $-35.40M avg. -61.29% |
EPS
% change YoY
| -$17.78 N/A | -$11.91 33.01% | -$4.24 64.39% | Avg: -$2.3 Low: -$3.58 High: -$1.61 avg. 45.67% | Avg: -$2.65 Low: -$4.11 High: -$1.19 avg. -15.05% | Avg: -$1.86 Low: -$2.09 High: -$1.49 avg. 29.81% | Avg: $0.69 Low: $0.55 High: $0.77 avg. 136.82% |
Operating Expenses
% change YoY
| $12.42M N/A | $19.93M 60.43% | $8.54M -57.14% | Avg: $40.24M Low: $34.06M High: $44.10M avg. 371.00% | Avg: $236.75M Low: $200.40M High: $259.50M avg. 488.31% | Avg: $762.66M Low: $645.57M High: $835.95M avg. 222.13% | Avg: $1.23B Low: $1.04B High: $1.34B avg. 61.29% |
FAQ
What is Plus Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 8.86% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -11.24M, average is -29.06M and high is -5.05M.
What is Plus Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 182.52% in 2025-2028.
We have gathered data from 2 analysts. Their low revenue estimate is $2.42M, average is $2.86M and high is $3.14M.
What is Plus Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 49.31% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$3.58, average is -$2.3 and high is $-1.61.